Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.

Oda, Naohiro; Miyoshi, Keiji; Morichika, Daisuke; Beika, Yuka; Taki, Takahiro; Mitani, Reo; Okada, Toshiaki; Takata, Ichiro

Oda, Naohiro; Miyoshi, Keiji; Morichika, Daisuke; Beika, Yuka; Taki, Takahiro; Mitani, Reo; Okada, Toshiaki; Takata, Ichiro.

Afiliação

Oda N; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Miyoshi K; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Morichika D; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Beika Y; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Taki T; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Mitani R; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Okada T; Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
Takata I; Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.

Clin Case Rep ; 9(7): e04459, 2021 Jul.

Article em En | MEDLINE | ID: mdl-34257986

ABSTRACT

ABSTRACT

COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.

Palavras-chave

COVID19; baricitinib; immune checkpoint inhibitor; immunerelated adverse event; lung cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Case Rep Ano de publicação: 2021 Tipo de documento: Article